Protocol to utilize fresh uncultured human lung tumor cells for personalized functional diagnostics
Year: 2022
Type: article
Abstract: Drug sensitivity data acquired from solid tumor-derived cultures are often unsuitable for personalized treatment guidance due to the lengthy turnaround time. Here, we present a protocol for determining ex vivo drug sensitivities using fresh uncultured human lung tumor-derived EpCAM + epithelial cells (FUTCs). We describe steps for drug testing in FUTCs to identify tumor cell-selective single or combination therapy in 72 h of sample processing. The FUTC-based approach can also be used to predict in vivo resistance to known targeted therapies. For complete details on the use and execution of this protocol, please refer to Talwelkar et al. (2021) .
Source: STAR Protocols
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,500
Funders: Ida Montinin Säätiö, Helsingin Yliopisto, Suomen Lääketieteen Säätiö, Medicinska Understödsföreningen Liv och Hälsa, European Commission, Academy of Finland, Novo Nordisk, Väinö ja Laina Kiven Säätiö, Novo Nordisk Fonden, Biocenter Finland, Horizon 2020 Framework Programme, Helsinki Institute of Life Science, Helsingin Yliopisto, Horizon 2020, H2020 Marie Skłodowska-Curie Actions
Awards: G155838707, G3589578894, G399059165, G434337789, Innovative strategies for cancer prevention with focus on sex hormone signaling and chronic inflammation, Development of new antimicrobial nanostructured durable coatings for fuel tanks, Innovative strategies for cancer prevention with focus on sex hormone signaling and chronic inflammation, G7044228676, G7940337353
OpenAlex ID: W4297314868
